nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—Valrubicin—urinary bladder cancer	0.158	0.742	CrCtD
Doxorubicin—Anthracyclines—Epirubicin—urinary bladder cancer	0.0959	0.438	CiPCiCtD
Doxorubicin—Topoisomerase Inhibitors—Etoposide—urinary bladder cancer	0.0728	0.333	CiPCiCtD
Doxorubicin—POR—urinary bladder cancer	0.0599	0.635	CbGaD
Doxorubicin—Epirubicin—urinary bladder cancer	0.0548	0.258	CrCtD
Doxorubicin—Topoisomerase Inhibitors—Epirubicin—urinary bladder cancer	0.0501	0.229	CiPCiCtD
Doxorubicin—prostate cancer—urinary bladder cancer	0.0409	0.294	CtDrD
Doxorubicin—muscle cancer—urinary bladder cancer	0.0354	0.255	CtDrD
Doxorubicin—NQO1—urinary bladder cancer	0.0344	0.365	CbGaD
Doxorubicin—Idarubicin—Valrubicin—urinary bladder cancer	0.0339	0.247	CrCrCtD
Doxorubicin—Epirubicin—Valrubicin—urinary bladder cancer	0.0339	0.247	CrCrCtD
Doxorubicin—Daunorubicin—Valrubicin—urinary bladder cancer	0.0339	0.247	CrCrCtD
Doxorubicin—testicular cancer—urinary bladder cancer	0.0332	0.239	CtDrD
Doxorubicin—kidney cancer—urinary bladder cancer	0.0296	0.213	CtDrD
Doxorubicin—POR—Mitomycin—urinary bladder cancer	0.0191	0.149	CbGbCtD
Doxorubicin—TOP2A—Valrubicin—urinary bladder cancer	0.0163	0.127	CbGbCtD
Doxorubicin—AURKA—Epirubicin—urinary bladder cancer	0.0121	0.0946	CbGbCtD
Doxorubicin—DHCR7—Epirubicin—urinary bladder cancer	0.0121	0.0946	CbGbCtD
Doxorubicin—YWHAG—Epirubicin—urinary bladder cancer	0.0121	0.0946	CbGbCtD
Doxorubicin—Idarubicin—Epirubicin—urinary bladder cancer	0.0118	0.0861	CrCrCtD
Doxorubicin—Valrubicin—Epirubicin—urinary bladder cancer	0.0118	0.0861	CrCrCtD
Doxorubicin—Daunorubicin—Epirubicin—urinary bladder cancer	0.0118	0.0861	CrCrCtD
Doxorubicin—NQO1—Carboplatin—urinary bladder cancer	0.00514	0.0401	CbGbCtD
Doxorubicin—NQO1—Cisplatin—urinary bladder cancer	0.0044	0.0342	CbGbCtD
Doxorubicin—ABCC10—Gemcitabine—urinary bladder cancer	0.00387	0.0301	CbGbCtD
Doxorubicin—ABCC6—Cisplatin—urinary bladder cancer	0.00368	0.0286	CbGbCtD
Doxorubicin—ABCC6—Etoposide—urinary bladder cancer	0.00361	0.0281	CbGbCtD
Doxorubicin—ABCC10—Etoposide—urinary bladder cancer	0.00276	0.0215	CbGbCtD
Doxorubicin—XDH—Carboplatin—urinary bladder cancer	0.00269	0.0209	CbGbCtD
Doxorubicin—TOP2A—Epirubicin—urinary bladder cancer	0.00247	0.0192	CbGbCtD
Doxorubicin—XDH—Cisplatin—urinary bladder cancer	0.0023	0.0179	CbGbCtD
Doxorubicin—ABCC3—Fluorouracil—urinary bladder cancer	0.00208	0.0162	CbGbCtD
Doxorubicin—TOP2A—Etoposide—urinary bladder cancer	0.00192	0.015	CbGbCtD
Doxorubicin—CYP2B6—Thiotepa—urinary bladder cancer	0.00185	0.0144	CbGbCtD
Doxorubicin—ABCC10—Methotrexate—urinary bladder cancer	0.00182	0.0142	CbGbCtD
Doxorubicin—ABCC3—Cisplatin—urinary bladder cancer	0.00177	0.0138	CbGbCtD
Doxorubicin—ABCC3—Etoposide—urinary bladder cancer	0.00174	0.0135	CbGbCtD
Doxorubicin—ABCC1—Epirubicin—urinary bladder cancer	0.00137	0.0107	CbGbCtD
Doxorubicin—ABCB1—Mitomycin—urinary bladder cancer	0.00125	0.00974	CbGbCtD
Doxorubicin—ABCC3—Methotrexate—urinary bladder cancer	0.00115	0.00893	CbGbCtD
Doxorubicin—ABCC1—Etoposide—urinary bladder cancer	0.00107	0.0083	CbGbCtD
Doxorubicin—ABCC2—Carboplatin—urinary bladder cancer	0.000939	0.00732	CbGbCtD
Doxorubicin—ABCG2—Fluorouracil—urinary bladder cancer	0.000854	0.00665	CbGbCtD
Doxorubicin—ABCG2—Carboplatin—urinary bladder cancer	0.000849	0.00661	CbGbCtD
Doxorubicin—ABCC2—Cisplatin—urinary bladder cancer	0.000803	0.00625	CbGbCtD
Doxorubicin—ABCC2—Etoposide—urinary bladder cancer	0.000789	0.00614	CbGbCtD
Doxorubicin—NOS1—penis—urinary bladder cancer	0.000731	0.0448	CbGeAlD
Doxorubicin—ABCG2—Cisplatin—urinary bladder cancer	0.000726	0.00565	CbGbCtD
Doxorubicin—ABCG2—Etoposide—urinary bladder cancer	0.000713	0.00555	CbGbCtD
Doxorubicin—ABCC1—Methotrexate—urinary bladder cancer	0.000704	0.00548	CbGbCtD
Doxorubicin—CYP3A4—Thiotepa—urinary bladder cancer	0.000568	0.00442	CbGbCtD
Doxorubicin—NOS3—penis—urinary bladder cancer	0.000555	0.034	CbGeAlD
Doxorubicin—ABCC2—Methotrexate—urinary bladder cancer	0.000521	0.00406	CbGbCtD
Doxorubicin—CYP2B6—Cisplatin—urinary bladder cancer	0.00051	0.00397	CbGbCtD
Doxorubicin—ABCG2—Methotrexate—urinary bladder cancer	0.000471	0.00367	CbGbCtD
Doxorubicin—NOS3—umbilical vein—urinary bladder cancer	0.000458	0.0281	CbGeAlD
Doxorubicin—ABCB1—Gemcitabine—urinary bladder cancer	0.00036	0.0028	CbGbCtD
Doxorubicin—Epirubicin—UGT2B7—urinary bladder cancer	0.00036	0.536	CrCbGaD
Doxorubicin—Daunorubicin—POR—urinary bladder cancer	0.000312	0.465	CrCbGaD
Doxorubicin—ABCB8—prostate gland—urinary bladder cancer	0.00031	0.019	CbGeAlD
Doxorubicin—CBR3—prostate gland—urinary bladder cancer	0.000298	0.0183	CbGeAlD
Doxorubicin—SLC22A16—renal system—urinary bladder cancer	0.000272	0.0166	CbGeAlD
Doxorubicin—ABCB1—Cisplatin—urinary bladder cancer	0.000262	0.00204	CbGbCtD
Doxorubicin—ABCB1—Etoposide—urinary bladder cancer	0.000257	0.002	CbGbCtD
Doxorubicin—CBR3—seminal vesicle—urinary bladder cancer	0.000252	0.0155	CbGeAlD
Doxorubicin—AKR1A1—prostate gland—urinary bladder cancer	0.00023	0.0141	CbGeAlD
Doxorubicin—SLC22A16—female reproductive system—urinary bladder cancer	0.000217	0.0133	CbGeAlD
Doxorubicin—ABCB8—renal system—urinary bladder cancer	0.000211	0.0129	CbGeAlD
Doxorubicin—NDUFS7—prostate gland—urinary bladder cancer	0.000209	0.0128	CbGeAlD
Doxorubicin—CBR3—urethra—urinary bladder cancer	0.0002	0.0122	CbGeAlD
Doxorubicin—AKR1A1—seminal vesicle—urinary bladder cancer	0.000195	0.0119	CbGeAlD
Doxorubicin—NOS1—prostate gland—urinary bladder cancer	0.000174	0.0107	CbGeAlD
Doxorubicin—NDUFS2—prostate gland—urinary bladder cancer	0.000173	0.0106	CbGeAlD
Doxorubicin—NDUFS3—prostate gland—urinary bladder cancer	0.000171	0.0105	CbGeAlD
Doxorubicin—ABCB1—Methotrexate—urinary bladder cancer	0.00017	0.00132	CbGbCtD
Doxorubicin—ABCB8—female reproductive system—urinary bladder cancer	0.000169	0.0104	CbGeAlD
Doxorubicin—AKR1A1—smooth muscle tissue—urinary bladder cancer	0.000163	0.00999	CbGeAlD
Doxorubicin—CBR3—female reproductive system—urinary bladder cancer	0.000163	0.00998	CbGeAlD
Doxorubicin—DHCR7—prostate gland—urinary bladder cancer	0.000163	0.00997	CbGeAlD
Doxorubicin—AKR1A1—renal system—urinary bladder cancer	0.000157	0.00962	CbGeAlD
Doxorubicin—AKR1A1—urethra—urinary bladder cancer	0.000154	0.00945	CbGeAlD
Doxorubicin—CYP3A4—Etoposide—urinary bladder cancer	0.000154	0.0012	CbGbCtD
Doxorubicin—YWHAG—prostate gland—urinary bladder cancer	0.000149	0.00915	CbGeAlD
Doxorubicin—CBR3—vagina—urinary bladder cancer	0.000147	0.00902	CbGeAlD
Doxorubicin—NDUFS2—seminal vesicle—urinary bladder cancer	0.000147	0.00899	CbGeAlD
Doxorubicin—XDH—prostate gland—urinary bladder cancer	0.000146	0.00893	CbGeAlD
Doxorubicin—NDUFS3—seminal vesicle—urinary bladder cancer	0.000145	0.00888	CbGeAlD
Doxorubicin—NDUFS7—renal system—urinary bladder cancer	0.000143	0.00874	CbGeAlD
Doxorubicin—DHCR7—seminal vesicle—urinary bladder cancer	0.000138	0.00844	CbGeAlD
Doxorubicin—RALBP1—prostate gland—urinary bladder cancer	0.000135	0.00827	CbGeAlD
Doxorubicin—NOS3—prostate gland—urinary bladder cancer	0.000133	0.00813	CbGeAlD
Doxorubicin—AURKA—renal system—urinary bladder cancer	0.000133	0.00813	CbGeAlD
Doxorubicin—NOS1—epithelium—urinary bladder cancer	0.000128	0.00786	CbGeAlD
Doxorubicin—YWHAG—seminal vesicle—urinary bladder cancer	0.000126	0.00774	CbGeAlD
Doxorubicin—CBR1—prostate gland—urinary bladder cancer	0.000126	0.00772	CbGeAlD
Doxorubicin—AKR1A1—female reproductive system—urinary bladder cancer	0.000126	0.0077	CbGeAlD
Doxorubicin—AKR1C3—prostate gland—urinary bladder cancer	0.000124	0.00762	CbGeAlD
Doxorubicin—NOS1—smooth muscle tissue—urinary bladder cancer	0.000124	0.00757	CbGeAlD
Doxorubicin—NDUFS2—smooth muscle tissue—urinary bladder cancer	0.000123	0.00753	CbGeAlD
Doxorubicin—NDUFS3—smooth muscle tissue—urinary bladder cancer	0.000121	0.00743	CbGeAlD
Doxorubicin—NOS1—renal system—urinary bladder cancer	0.000119	0.00729	CbGeAlD
Doxorubicin—NDUFS2—renal system—urinary bladder cancer	0.000118	0.00724	CbGeAlD
Doxorubicin—NDUFS3—renal system—urinary bladder cancer	0.000117	0.00716	CbGeAlD
Doxorubicin—NDUFS2—urethra—urinary bladder cancer	0.000116	0.00712	CbGeAlD
Doxorubicin—NDUFS3—urethra—urinary bladder cancer	0.000115	0.00703	CbGeAlD
Doxorubicin—NDUFS7—female reproductive system—urinary bladder cancer	0.000114	0.007	CbGeAlD
Doxorubicin—RALBP1—seminal vesicle—urinary bladder cancer	0.000114	0.00699	CbGeAlD
Doxorubicin—AKR1A1—vagina—urinary bladder cancer	0.000114	0.00697	CbGeAlD
Doxorubicin—POR—prostate gland—urinary bladder cancer	0.000114	0.00696	CbGeAlD
Doxorubicin—DHCR7—urethra—urinary bladder cancer	0.000109	0.00668	CbGeAlD
Doxorubicin—ABCC6—renal system—urinary bladder cancer	0.000108	0.00663	CbGeAlD
Doxorubicin—CBR1—seminal vesicle—urinary bladder cancer	0.000106	0.00653	CbGeAlD
Doxorubicin—AURKA—female reproductive system—urinary bladder cancer	0.000106	0.00651	CbGeAlD
Doxorubicin—TOP2A—prostate gland—urinary bladder cancer	0.000106	0.00649	CbGeAlD
Doxorubicin—YWHAG—smooth muscle tissue—urinary bladder cancer	0.000106	0.00648	CbGeAlD
Doxorubicin—AKR1C3—seminal vesicle—urinary bladder cancer	0.000105	0.00645	CbGeAlD
Doxorubicin—NDUFS7—vagina—urinary bladder cancer	0.000103	0.00633	CbGeAlD
Doxorubicin—CYP3A4—urine—urinary bladder cancer	0.000102	0.00627	CbGeAlD
Doxorubicin—YWHAG—renal system—urinary bladder cancer	0.000102	0.00624	CbGeAlD
Doxorubicin—NQO1—prostate gland—urinary bladder cancer	0.000101	0.00618	CbGeAlD
Doxorubicin—CYP2D6—urine—urinary bladder cancer	0.000101	0.00617	CbGeAlD
Doxorubicin—YWHAG—urethra—urinary bladder cancer	0.0001	0.00613	CbGeAlD
Doxorubicin—XDH—renal system—urinary bladder cancer	9.93e-05	0.00608	CbGeAlD
Doxorubicin—ABCB8—lymph node—urinary bladder cancer	9.89e-05	0.00606	CbGeAlD
Doxorubicin—NOS3—epithelium—urinary bladder cancer	9.75e-05	0.00598	CbGeAlD
Doxorubicin—AURKA—vagina—urinary bladder cancer	9.6e-05	0.00589	CbGeAlD
Doxorubicin—POR—seminal vesicle—urinary bladder cancer	9.6e-05	0.00589	CbGeAlD
Doxorubicin—RALBP1—smooth muscle tissue—urinary bladder cancer	9.55e-05	0.00585	CbGeAlD
Doxorubicin—NOS1—female reproductive system—urinary bladder cancer	9.52e-05	0.00584	CbGeAlD
Doxorubicin—CBR3—lymph node—urinary bladder cancer	9.52e-05	0.00584	CbGeAlD
Doxorubicin—NDUFS2—female reproductive system—urinary bladder cancer	9.46e-05	0.0058	CbGeAlD
Doxorubicin—NOS3—smooth muscle tissue—urinary bladder cancer	9.39e-05	0.00576	CbGeAlD
Doxorubicin—NDUFS3—female reproductive system—urinary bladder cancer	9.35e-05	0.00573	CbGeAlD
Doxorubicin—RALBP1—renal system—urinary bladder cancer	9.19e-05	0.00563	CbGeAlD
Doxorubicin—ABCC3—prostate gland—urinary bladder cancer	9.05e-05	0.00555	CbGeAlD
Doxorubicin—NOS3—renal system—urinary bladder cancer	9.04e-05	0.00554	CbGeAlD
Doxorubicin—RALBP1—urethra—urinary bladder cancer	9.03e-05	0.00553	CbGeAlD
Doxorubicin—ABCC10—prostate gland—urinary bladder cancer	9.01e-05	0.00552	CbGeAlD
Doxorubicin—DHCR7—female reproductive system—urinary bladder cancer	8.88e-05	0.00544	CbGeAlD
Doxorubicin—AKR1C3—smooth muscle tissue—urinary bladder cancer	8.8e-05	0.0054	CbGeAlD
Doxorubicin—CBR1—renal system—urinary bladder cancer	8.58e-05	0.00526	CbGeAlD
Doxorubicin—NDUFS2—vagina—urinary bladder cancer	8.56e-05	0.00525	CbGeAlD
Doxorubicin—NQO1—seminal vesicle—urinary bladder cancer	8.53e-05	0.00523	CbGeAlD
Doxorubicin—NDUFS3—vagina—urinary bladder cancer	8.46e-05	0.00518	CbGeAlD
Doxorubicin—CBR1—urethra—urinary bladder cancer	8.43e-05	0.00517	CbGeAlD
Doxorubicin—AKR1C3—urethra—urinary bladder cancer	8.32e-05	0.0051	CbGeAlD
Doxorubicin—YWHAG—female reproductive system—urinary bladder cancer	8.15e-05	0.005	CbGeAlD
Doxorubicin—DHCR7—vagina—urinary bladder cancer	8.03e-05	0.00492	CbGeAlD
Doxorubicin—XDH—female reproductive system—urinary bladder cancer	7.95e-05	0.00487	CbGeAlD
Doxorubicin—ABCC10—seminal vesicle—urinary bladder cancer	7.62e-05	0.00467	CbGeAlD
Doxorubicin—POR—urethra—urinary bladder cancer	7.6e-05	0.00466	CbGeAlD
Doxorubicin—NQO1—epithelium—urinary bladder cancer	7.41e-05	0.00454	CbGeAlD
Doxorubicin—YWHAG—vagina—urinary bladder cancer	7.37e-05	0.00452	CbGeAlD
Doxorubicin—RALBP1—female reproductive system—urinary bladder cancer	7.36e-05	0.00451	CbGeAlD
Doxorubicin—AKR1A1—lymph node—urinary bladder cancer	7.35e-05	0.00451	CbGeAlD
Doxorubicin—NOS3—female reproductive system—urinary bladder cancer	7.24e-05	0.00444	CbGeAlD
Doxorubicin—ABCC2—prostate gland—urinary bladder cancer	7.23e-05	0.00443	CbGeAlD
Doxorubicin—XDH—vagina—urinary bladder cancer	7.19e-05	0.00441	CbGeAlD
Doxorubicin—NQO1—smooth muscle tissue—urinary bladder cancer	7.14e-05	0.00438	CbGeAlD
Doxorubicin—CYP1B1—prostate gland—urinary bladder cancer	7.08e-05	0.00434	CbGeAlD
Doxorubicin—NQO1—renal system—urinary bladder cancer	6.87e-05	0.00421	CbGeAlD
Doxorubicin—CBR1—female reproductive system—urinary bladder cancer	6.87e-05	0.00421	CbGeAlD
Doxorubicin—CBR3—Idarubicin—Valrubicin—urinary bladder cancer	6.79e-05	0.101	CbGdCrCtD
Doxorubicin—CBR3—Daunorubicin—Valrubicin—urinary bladder cancer	6.79e-05	0.101	CbGdCrCtD
Doxorubicin—CBR3—Epirubicin—Valrubicin—urinary bladder cancer	6.79e-05	0.101	CbGdCrCtD
Doxorubicin—NQO1—urethra—urinary bladder cancer	6.75e-05	0.00414	CbGeAlD
Doxorubicin—NDUFS7—lymph node—urinary bladder cancer	6.68e-05	0.0041	CbGeAlD
Doxorubicin—RALBP1—vagina—urinary bladder cancer	6.66e-05	0.00408	CbGeAlD
Doxorubicin—NOS3—vagina—urinary bladder cancer	6.55e-05	0.00401	CbGeAlD
Doxorubicin—ABCC1—prostate gland—urinary bladder cancer	6.37e-05	0.00391	CbGeAlD
Doxorubicin—CBR1—vagina—urinary bladder cancer	6.21e-05	0.00381	CbGeAlD
Doxorubicin—AURKA—lymph node—urinary bladder cancer	6.21e-05	0.00381	CbGeAlD
Doxorubicin—ABCC3—renal system—urinary bladder cancer	6.17e-05	0.00378	CbGeAlD
Doxorubicin—ABCC10—renal system—urinary bladder cancer	6.14e-05	0.00376	CbGeAlD
Doxorubicin—AKR1C3—vagina—urinary bladder cancer	6.14e-05	0.00376	CbGeAlD
Doxorubicin—ABCC10—urethra—urinary bladder cancer	6.03e-05	0.0037	CbGeAlD
Doxorubicin—POR—vagina—urinary bladder cancer	5.6e-05	0.00344	CbGeAlD
Doxorubicin—NDUFS2—lymph node—urinary bladder cancer	5.54e-05	0.00339	CbGeAlD
Doxorubicin—NQO1—female reproductive system—urinary bladder cancer	5.51e-05	0.00337	CbGeAlD
Doxorubicin—NDUFS3—lymph node—urinary bladder cancer	5.47e-05	0.00335	CbGeAlD
Doxorubicin—ABCC1—seminal vesicle—urinary bladder cancer	5.39e-05	0.0033	CbGeAlD
Doxorubicin—ABCG2—prostate gland—urinary bladder cancer	5.27e-05	0.00323	CbGeAlD
Doxorubicin—TOP2A—vagina—urinary bladder cancer	5.22e-05	0.0032	CbGeAlD
Doxorubicin—DHCR7—lymph node—urinary bladder cancer	5.2e-05	0.00319	CbGeAlD
Doxorubicin—ABCC6—Podofilox—Etoposide—urinary bladder cancer	5.03e-05	0.0752	CbGdCrCtD
Doxorubicin—CYP1B1—smooth muscle tissue—urinary bladder cancer	5.02e-05	0.00307	CbGeAlD
Doxorubicin—NQO1—vagina—urinary bladder cancer	4.98e-05	0.00305	CbGeAlD
Doxorubicin—ABCC3—female reproductive system—urinary bladder cancer	4.94e-05	0.00303	CbGeAlD
Doxorubicin—ABCC2—renal system—urinary bladder cancer	4.93e-05	0.00302	CbGeAlD
Doxorubicin—ABCC10—female reproductive system—urinary bladder cancer	4.92e-05	0.00301	CbGeAlD
Doxorubicin—CYP1B1—renal system—urinary bladder cancer	4.83e-05	0.00296	CbGeAlD
Doxorubicin—YWHAG—lymph node—urinary bladder cancer	4.77e-05	0.00292	CbGeAlD
Doxorubicin—CBR3—Teniposide—Etoposide—urinary bladder cancer	4.53e-05	0.0677	CbGdCrCtD
Doxorubicin—ABCG2—seminal vesicle—urinary bladder cancer	4.46e-05	0.00273	CbGeAlD
Doxorubicin—ABCC10—vagina—urinary bladder cancer	4.45e-05	0.00273	CbGeAlD
Doxorubicin—AKR1C3—Podofilox—Etoposide—urinary bladder cancer	4.4e-05	0.0657	CbGdCrCtD
Doxorubicin—RALBP1—lymph node—urinary bladder cancer	4.31e-05	0.00264	CbGeAlD
Doxorubicin—ABCC1—urethra—urinary bladder cancer	4.27e-05	0.00261	CbGeAlD
Doxorubicin—NOS3—lymph node—urinary bladder cancer	4.24e-05	0.0026	CbGeAlD
Doxorubicin—CBR1—lymph node—urinary bladder cancer	4.02e-05	0.00246	CbGeAlD
Doxorubicin—AKR1C3—lymph node—urinary bladder cancer	3.97e-05	0.00243	CbGeAlD
Doxorubicin—ABCC2—female reproductive system—urinary bladder cancer	3.95e-05	0.00242	CbGeAlD
Doxorubicin—CYP1B1—female reproductive system—urinary bladder cancer	3.87e-05	0.00237	CbGeAlD
Doxorubicin—POR—lymph node—urinary bladder cancer	3.63e-05	0.00222	CbGeAlD
Doxorubicin—AURKA—Epirubicin—Valrubicin—urinary bladder cancer	3.58e-05	0.0534	CbGdCrCtD
Doxorubicin—AURKA—Idarubicin—Valrubicin—urinary bladder cancer	3.58e-05	0.0534	CbGdCrCtD
Doxorubicin—AURKA—Daunorubicin—Valrubicin—urinary bladder cancer	3.58e-05	0.0534	CbGdCrCtD
Doxorubicin—ABCG2—urethra—urinary bladder cancer	3.53e-05	0.00216	CbGeAlD
Doxorubicin—TOP2A—lymph node—urinary bladder cancer	3.38e-05	0.00207	CbGeAlD
Doxorubicin—CYP2B6—renal system—urinary bladder cancer	3.32e-05	0.00203	CbGeAlD
Doxorubicin—NQO1—lymph node—urinary bladder cancer	3.22e-05	0.00197	CbGeAlD
Doxorubicin—ABCC1—vagina—urinary bladder cancer	3.15e-05	0.00193	CbGeAlD
Doxorubicin—ABCC3—lymph node—urinary bladder cancer	2.89e-05	0.00177	CbGeAlD
Doxorubicin—ABCC10—lymph node—urinary bladder cancer	2.88e-05	0.00176	CbGeAlD
Doxorubicin—CYP2B6—female reproductive system—urinary bladder cancer	2.66e-05	0.00163	CbGeAlD
Doxorubicin—ABCG2—vagina—urinary bladder cancer	2.6e-05	0.0016	CbGeAlD
Doxorubicin—ABCB1—prostate gland—urinary bladder cancer	2.6e-05	0.00159	CbGeAlD
Doxorubicin—CYP3A4—renal system—urinary bladder cancer	2.5e-05	0.00154	CbGeAlD
Doxorubicin—CYP2D6—renal system—urinary bladder cancer	2.46e-05	0.00151	CbGeAlD
Doxorubicin—CYP2B6—vagina—urinary bladder cancer	2.4e-05	0.00147	CbGeAlD
Doxorubicin—AURKA—Teniposide—Etoposide—urinary bladder cancer	2.39e-05	0.0357	CbGdCrCtD
Doxorubicin—CBR3—Idarubicin—Epirubicin—urinary bladder cancer	2.36e-05	0.0353	CbGdCrCtD
Doxorubicin—CBR3—Daunorubicin—Epirubicin—urinary bladder cancer	2.36e-05	0.0353	CbGdCrCtD
Doxorubicin—ABCC2—lymph node—urinary bladder cancer	2.31e-05	0.00142	CbGeAlD
Doxorubicin—CYP1B1—lymph node—urinary bladder cancer	2.26e-05	0.00139	CbGeAlD
Doxorubicin—ABCB1—seminal vesicle—urinary bladder cancer	2.2e-05	0.00135	CbGeAlD
Doxorubicin—ABCC1—lymph node—urinary bladder cancer	2.03e-05	0.00125	CbGeAlD
Doxorubicin—CYP3A4—female reproductive system—urinary bladder cancer	2.01e-05	0.00123	CbGeAlD
Doxorubicin—CYP2D6—female reproductive system—urinary bladder cancer	1.97e-05	0.00121	CbGeAlD
Doxorubicin—ABCB1—epithelium—urinary bladder cancer	1.91e-05	0.00117	CbGeAlD
Doxorubicin—CBR3—Azacitidine—Gemcitabine—urinary bladder cancer	1.83e-05	0.0273	CbGdCrCtD
Doxorubicin—ABCB1—renal system—urinary bladder cancer	1.77e-05	0.00109	CbGeAlD
Doxorubicin—ABCB1—urethra—urinary bladder cancer	1.74e-05	0.00107	CbGeAlD
Doxorubicin—ABCG2—lymph node—urinary bladder cancer	1.68e-05	0.00103	CbGeAlD
Doxorubicin—ABCB1—female reproductive system—urinary bladder cancer	1.42e-05	0.00087	CbGeAlD
Doxorubicin—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	1.37e-05	0.0204	CbGdCrCtD
Doxorubicin—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	1.37e-05	0.0204	CbGdCrCtD
Doxorubicin—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	1.37e-05	0.0204	CbGdCrCtD
Doxorubicin—CBR1—Azacitidine—Gemcitabine—urinary bladder cancer	1.35e-05	0.0202	CbGdCrCtD
Doxorubicin—AURKA—Cytarabine—Gemcitabine—urinary bladder cancer	1.34e-05	0.0201	CbGdCrCtD
Doxorubicin—ABCB1—vagina—urinary bladder cancer	1.28e-05	0.000787	CbGeAlD
Doxorubicin—AURKA—Idarubicin—Epirubicin—urinary bladder cancer	1.25e-05	0.0186	CbGdCrCtD
Doxorubicin—AURKA—Daunorubicin—Epirubicin—urinary bladder cancer	1.25e-05	0.0186	CbGdCrCtD
Doxorubicin—TOP2A—Teniposide—Etoposide—urinary bladder cancer	9.12e-06	0.0136	CbGdCrCtD
Doxorubicin—TOP2A—Podofilox—Etoposide—urinary bladder cancer	9.12e-06	0.0136	CbGdCrCtD
Doxorubicin—ABCB1—lymph node—urinary bladder cancer	8.31e-06	0.000509	CbGeAlD
Doxorubicin—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	5.69e-06	0.000167	CcSEcCtD
Doxorubicin—Body temperature increased—Gemcitabine—urinary bladder cancer	5.66e-06	0.000166	CcSEcCtD
Doxorubicin—Renal failure—Methotrexate—urinary bladder cancer	5.64e-06	0.000166	CcSEcCtD
Doxorubicin—Neutropenia—Epirubicin—urinary bladder cancer	5.63e-06	0.000165	CcSEcCtD
Doxorubicin—Dysuria—Epirubicin—urinary bladder cancer	5.63e-06	0.000165	CcSEcCtD
Doxorubicin—Dizziness—Thiotepa—urinary bladder cancer	5.62e-06	0.000165	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	5.6e-06	0.000164	CcSEcCtD
Doxorubicin—Stomatitis—Methotrexate—urinary bladder cancer	5.59e-06	0.000164	CcSEcCtD
Doxorubicin—Urticaria—Fluorouracil—urinary bladder cancer	5.59e-06	0.000164	CcSEcCtD
Doxorubicin—Conjunctivitis—Methotrexate—urinary bladder cancer	5.58e-06	0.000164	CcSEcCtD
Doxorubicin—Pollakiuria—Epirubicin—urinary bladder cancer	5.56e-06	0.000163	CcSEcCtD
Doxorubicin—Body temperature increased—Fluorouracil—urinary bladder cancer	5.56e-06	0.000163	CcSEcCtD
Doxorubicin—Sweating—Methotrexate—urinary bladder cancer	5.5e-06	0.000161	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Epirubicin—urinary bladder cancer	5.5e-06	0.000161	CcSEcCtD
Doxorubicin—Feeling abnormal—Cisplatin—urinary bladder cancer	5.49e-06	0.000161	CcSEcCtD
Doxorubicin—Paraesthesia—Etoposide—urinary bladder cancer	5.49e-06	0.000161	CcSEcCtD
Doxorubicin—Weight increased—Epirubicin—urinary bladder cancer	5.48e-06	0.000161	CcSEcCtD
Doxorubicin—Haematuria—Methotrexate—urinary bladder cancer	5.47e-06	0.000161	CcSEcCtD
Doxorubicin—Weight decreased—Epirubicin—urinary bladder cancer	5.45e-06	0.00016	CcSEcCtD
Doxorubicin—Dyspnoea—Etoposide—urinary bladder cancer	5.45e-06	0.00016	CcSEcCtD
Doxorubicin—Hyperglycaemia—Epirubicin—urinary bladder cancer	5.43e-06	0.000159	CcSEcCtD
Doxorubicin—Somnolence—Etoposide—urinary bladder cancer	5.43e-06	0.000159	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Methotrexate—urinary bladder cancer	5.43e-06	0.000159	CcSEcCtD
Doxorubicin—Epistaxis—Methotrexate—urinary bladder cancer	5.41e-06	0.000159	CcSEcCtD
Doxorubicin—Vomiting—Thiotepa—urinary bladder cancer	5.41e-06	0.000159	CcSEcCtD
Doxorubicin—Pneumonia—Epirubicin—urinary bladder cancer	5.4e-06	0.000159	CcSEcCtD
Doxorubicin—Infestation NOS—Epirubicin—urinary bladder cancer	5.37e-06	0.000158	CcSEcCtD
Doxorubicin—Drowsiness—Epirubicin—urinary bladder cancer	5.37e-06	0.000158	CcSEcCtD
Doxorubicin—Infestation—Epirubicin—urinary bladder cancer	5.37e-06	0.000158	CcSEcCtD
Doxorubicin—Rash—Thiotepa—urinary bladder cancer	5.36e-06	0.000157	CcSEcCtD
Doxorubicin—Dermatitis—Thiotepa—urinary bladder cancer	5.36e-06	0.000157	CcSEcCtD
Doxorubicin—Agranulocytosis—Methotrexate—urinary bladder cancer	5.35e-06	0.000157	CcSEcCtD
Doxorubicin—Headache—Thiotepa—urinary bladder cancer	5.33e-06	0.000156	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	5.32e-06	0.000156	CcSEcCtD
Doxorubicin—Decreased appetite—Etoposide—urinary bladder cancer	5.31e-06	0.000156	CcSEcCtD
Doxorubicin—Renal failure—Epirubicin—urinary bladder cancer	5.28e-06	0.000155	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	5.27e-06	0.000155	CcSEcCtD
Doxorubicin—Body temperature increased—Cisplatin—urinary bladder cancer	5.27e-06	0.000155	CcSEcCtD
Doxorubicin—Fatigue—Etoposide—urinary bladder cancer	5.27e-06	0.000155	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Epirubicin—urinary bladder cancer	5.26e-06	0.000155	CcSEcCtD
Doxorubicin—Stomatitis—Epirubicin—urinary bladder cancer	5.23e-06	0.000154	CcSEcCtD
Doxorubicin—Jaundice—Epirubicin—urinary bladder cancer	5.23e-06	0.000154	CcSEcCtD
Doxorubicin—Constipation—Etoposide—urinary bladder cancer	5.22e-06	0.000153	CcSEcCtD
Doxorubicin—Pain—Etoposide—urinary bladder cancer	5.22e-06	0.000153	CcSEcCtD
Doxorubicin—Urinary tract infection—Epirubicin—urinary bladder cancer	5.22e-06	0.000153	CcSEcCtD
Doxorubicin—Conjunctivitis—Epirubicin—urinary bladder cancer	5.22e-06	0.000153	CcSEcCtD
Doxorubicin—Hypersensitivity—Fluorouracil—urinary bladder cancer	5.18e-06	0.000152	CcSEcCtD
Doxorubicin—Haemoglobin—Methotrexate—urinary bladder cancer	5.18e-06	0.000152	CcSEcCtD
Doxorubicin—Haemorrhage—Methotrexate—urinary bladder cancer	5.15e-06	0.000151	CcSEcCtD
Doxorubicin—Hepatitis—Methotrexate—urinary bladder cancer	5.15e-06	0.000151	CcSEcCtD
Doxorubicin—Sweating—Epirubicin—urinary bladder cancer	5.15e-06	0.000151	CcSEcCtD
Doxorubicin—Asthenia—Gemcitabine—urinary bladder cancer	5.13e-06	0.000151	CcSEcCtD
Doxorubicin—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	5.13e-06	0.00766	CbGdCrCtD
Doxorubicin—Haematuria—Epirubicin—urinary bladder cancer	5.12e-06	0.00015	CcSEcCtD
Doxorubicin—Pharyngitis—Methotrexate—urinary bladder cancer	5.11e-06	0.00015	CcSEcCtD
Doxorubicin—Urinary tract disorder—Methotrexate—urinary bladder cancer	5.09e-06	0.000149	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Epirubicin—urinary bladder cancer	5.08e-06	0.000149	CcSEcCtD
Doxorubicin—Epistaxis—Epirubicin—urinary bladder cancer	5.06e-06	0.000149	CcSEcCtD
Doxorubicin—Pruritus—Gemcitabine—urinary bladder cancer	5.06e-06	0.000149	CcSEcCtD
Doxorubicin—Nausea—Thiotepa—urinary bladder cancer	5.05e-06	0.000148	CcSEcCtD
Doxorubicin—Urethral disorder—Methotrexate—urinary bladder cancer	5.05e-06	0.000148	CcSEcCtD
Doxorubicin—Sinusitis—Epirubicin—urinary bladder cancer	5.04e-06	0.000148	CcSEcCtD
Doxorubicin—Feeling abnormal—Etoposide—urinary bladder cancer	5.03e-06	0.000148	CcSEcCtD
Doxorubicin—Agranulocytosis—Epirubicin—urinary bladder cancer	5.01e-06	0.000147	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Etoposide—urinary bladder cancer	5e-06	0.000147	CcSEcCtD
Doxorubicin—Pruritus—Fluorouracil—urinary bladder cancer	4.98e-06	0.000146	CcSEcCtD
Doxorubicin—Visual impairment—Methotrexate—urinary bladder cancer	4.96e-06	0.000146	CcSEcCtD
Doxorubicin—Hypersensitivity—Cisplatin—urinary bladder cancer	4.91e-06	0.000144	CcSEcCtD
Doxorubicin—Bradycardia—Epirubicin—urinary bladder cancer	4.91e-06	0.000144	CcSEcCtD
Doxorubicin—Diarrhoea—Gemcitabine—urinary bladder cancer	4.89e-06	0.000144	CcSEcCtD
Doxorubicin—Erythema multiforme—Methotrexate—urinary bladder cancer	4.87e-06	0.000143	CcSEcCtD
Doxorubicin—Urticaria—Etoposide—urinary bladder cancer	4.85e-06	0.000142	CcSEcCtD
Doxorubicin—Haemoglobin—Epirubicin—urinary bladder cancer	4.84e-06	0.000142	CcSEcCtD
Doxorubicin—Rhinitis—Epirubicin—urinary bladder cancer	4.83e-06	0.000142	CcSEcCtD
Doxorubicin—Body temperature increased—Etoposide—urinary bladder cancer	4.83e-06	0.000142	CcSEcCtD
Doxorubicin—Abdominal pain—Etoposide—urinary bladder cancer	4.83e-06	0.000142	CcSEcCtD
Doxorubicin—Haemorrhage—Epirubicin—urinary bladder cancer	4.82e-06	0.000141	CcSEcCtD
Doxorubicin—Hepatitis—Epirubicin—urinary bladder cancer	4.82e-06	0.000141	CcSEcCtD
Doxorubicin—Eye disorder—Methotrexate—urinary bladder cancer	4.81e-06	0.000141	CcSEcCtD
Doxorubicin—Diarrhoea—Fluorouracil—urinary bladder cancer	4.81e-06	0.000141	CcSEcCtD
Doxorubicin—Tinnitus—Methotrexate—urinary bladder cancer	4.8e-06	0.000141	CcSEcCtD
Doxorubicin—Hypoaesthesia—Epirubicin—urinary bladder cancer	4.8e-06	0.000141	CcSEcCtD
Doxorubicin—Asthenia—Cisplatin—urinary bladder cancer	4.78e-06	0.00014	CcSEcCtD
Doxorubicin—Pharyngitis—Epirubicin—urinary bladder cancer	4.78e-06	0.00014	CcSEcCtD
Doxorubicin—Cardiac disorder—Methotrexate—urinary bladder cancer	4.78e-06	0.00014	CcSEcCtD
Doxorubicin—Urinary tract disorder—Epirubicin—urinary bladder cancer	4.76e-06	0.00014	CcSEcCtD
Doxorubicin—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	4.76e-06	0.0071	CbGdCrCtD
Doxorubicin—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	4.76e-06	0.0071	CbGdCrCtD
Doxorubicin—Oedema peripheral—Epirubicin—urinary bladder cancer	4.75e-06	0.000139	CcSEcCtD
Doxorubicin—Connective tissue disorder—Epirubicin—urinary bladder cancer	4.74e-06	0.000139	CcSEcCtD
Doxorubicin—Urethral disorder—Epirubicin—urinary bladder cancer	4.72e-06	0.000139	CcSEcCtD
Doxorubicin—Angiopathy—Methotrexate—urinary bladder cancer	4.67e-06	0.000137	CcSEcCtD
Doxorubicin—Immune system disorder—Methotrexate—urinary bladder cancer	4.65e-06	0.000137	CcSEcCtD
Doxorubicin—Dizziness—Fluorouracil—urinary bladder cancer	4.65e-06	0.000137	CcSEcCtD
Doxorubicin—Visual impairment—Epirubicin—urinary bladder cancer	4.64e-06	0.000136	CcSEcCtD
Doxorubicin—Mediastinal disorder—Methotrexate—urinary bladder cancer	4.64e-06	0.000136	CcSEcCtD
Doxorubicin—Chills—Methotrexate—urinary bladder cancer	4.62e-06	0.000136	CcSEcCtD
Doxorubicin—Diarrhoea—Cisplatin—urinary bladder cancer	4.56e-06	0.000134	CcSEcCtD
Doxorubicin—Erythema multiforme—Epirubicin—urinary bladder cancer	4.56e-06	0.000134	CcSEcCtD
Doxorubicin—Alopecia—Methotrexate—urinary bladder cancer	4.55e-06	0.000134	CcSEcCtD
Doxorubicin—Vomiting—Gemcitabine—urinary bladder cancer	4.55e-06	0.000134	CcSEcCtD
Doxorubicin—Mental disorder—Methotrexate—urinary bladder cancer	4.51e-06	0.000132	CcSEcCtD
Doxorubicin—Rash—Gemcitabine—urinary bladder cancer	4.51e-06	0.000132	CcSEcCtD
Doxorubicin—Dermatitis—Gemcitabine—urinary bladder cancer	4.51e-06	0.000132	CcSEcCtD
Doxorubicin—Eye disorder—Epirubicin—urinary bladder cancer	4.5e-06	0.000132	CcSEcCtD
Doxorubicin—Hypersensitivity—Etoposide—urinary bladder cancer	4.5e-06	0.000132	CcSEcCtD
Doxorubicin—Tinnitus—Epirubicin—urinary bladder cancer	4.49e-06	0.000132	CcSEcCtD
Doxorubicin—Erythema—Methotrexate—urinary bladder cancer	4.48e-06	0.000132	CcSEcCtD
Doxorubicin—Malnutrition—Methotrexate—urinary bladder cancer	4.48e-06	0.000132	CcSEcCtD
Doxorubicin—Headache—Gemcitabine—urinary bladder cancer	4.48e-06	0.000132	CcSEcCtD
Doxorubicin—Cardiac disorder—Epirubicin—urinary bladder cancer	4.47e-06	0.000131	CcSEcCtD
Doxorubicin—Flushing—Epirubicin—urinary bladder cancer	4.47e-06	0.000131	CcSEcCtD
Doxorubicin—Vomiting—Fluorouracil—urinary bladder cancer	4.47e-06	0.000131	CcSEcCtD
Doxorubicin—Rash—Fluorouracil—urinary bladder cancer	4.43e-06	0.00013	CcSEcCtD
Doxorubicin—Dermatitis—Fluorouracil—urinary bladder cancer	4.43e-06	0.00013	CcSEcCtD
Doxorubicin—Headache—Fluorouracil—urinary bladder cancer	4.41e-06	0.000129	CcSEcCtD
Doxorubicin—Dysgeusia—Methotrexate—urinary bladder cancer	4.39e-06	0.000129	CcSEcCtD
Doxorubicin—Asthenia—Etoposide—urinary bladder cancer	4.38e-06	0.000129	CcSEcCtD
Doxorubicin—Angiopathy—Epirubicin—urinary bladder cancer	4.37e-06	0.000128	CcSEcCtD
Doxorubicin—Immune system disorder—Epirubicin—urinary bladder cancer	4.35e-06	0.000128	CcSEcCtD
Doxorubicin—Mediastinal disorder—Epirubicin—urinary bladder cancer	4.34e-06	0.000128	CcSEcCtD
Doxorubicin—Back pain—Methotrexate—urinary bladder cancer	4.34e-06	0.000127	CcSEcCtD
Doxorubicin—Chills—Epirubicin—urinary bladder cancer	4.32e-06	0.000127	CcSEcCtD
Doxorubicin—Pruritus—Etoposide—urinary bladder cancer	4.32e-06	0.000127	CcSEcCtD
Doxorubicin—Arrhythmia—Epirubicin—urinary bladder cancer	4.31e-06	0.000126	CcSEcCtD
Doxorubicin—Alopecia—Epirubicin—urinary bladder cancer	4.26e-06	0.000125	CcSEcCtD
Doxorubicin—Nausea—Gemcitabine—urinary bladder cancer	4.25e-06	0.000125	CcSEcCtD
Doxorubicin—Vomiting—Cisplatin—urinary bladder cancer	4.24e-06	0.000124	CcSEcCtD
Doxorubicin—Vision blurred—Methotrexate—urinary bladder cancer	4.23e-06	0.000124	CcSEcCtD
Doxorubicin—Mental disorder—Epirubicin—urinary bladder cancer	4.22e-06	0.000124	CcSEcCtD
Doxorubicin—Rash—Cisplatin—urinary bladder cancer	4.2e-06	0.000123	CcSEcCtD
Doxorubicin—Dermatitis—Cisplatin—urinary bladder cancer	4.2e-06	0.000123	CcSEcCtD
Doxorubicin—Erythema—Epirubicin—urinary bladder cancer	4.2e-06	0.000123	CcSEcCtD
Doxorubicin—Malnutrition—Epirubicin—urinary bladder cancer	4.2e-06	0.000123	CcSEcCtD
Doxorubicin—Diarrhoea—Etoposide—urinary bladder cancer	4.18e-06	0.000123	CcSEcCtD
Doxorubicin—Nausea—Fluorouracil—urinary bladder cancer	4.18e-06	0.000123	CcSEcCtD
Doxorubicin—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.16e-06	0.000122	CcSEcCtD
Doxorubicin—Anaemia—Methotrexate—urinary bladder cancer	4.14e-06	0.000122	CcSEcCtD
Doxorubicin—Flatulence—Epirubicin—urinary bladder cancer	4.13e-06	0.000121	CcSEcCtD
Doxorubicin—Tension—Epirubicin—urinary bladder cancer	4.12e-06	0.000121	CcSEcCtD
Doxorubicin—Dysgeusia—Epirubicin—urinary bladder cancer	4.11e-06	0.000121	CcSEcCtD
Doxorubicin—Nervousness—Epirubicin—urinary bladder cancer	4.07e-06	0.00012	CcSEcCtD
Doxorubicin—Back pain—Epirubicin—urinary bladder cancer	4.06e-06	0.000119	CcSEcCtD
Doxorubicin—Malaise—Methotrexate—urinary bladder cancer	4.04e-06	0.000119	CcSEcCtD
Doxorubicin—Dizziness—Etoposide—urinary bladder cancer	4.04e-06	0.000119	CcSEcCtD
Doxorubicin—Muscle spasms—Epirubicin—urinary bladder cancer	4.03e-06	0.000118	CcSEcCtD
Doxorubicin—Vertigo—Methotrexate—urinary bladder cancer	4.03e-06	0.000118	CcSEcCtD
Doxorubicin—Leukopenia—Methotrexate—urinary bladder cancer	4.01e-06	0.000118	CcSEcCtD
Doxorubicin—Nausea—Cisplatin—urinary bladder cancer	3.96e-06	0.000116	CcSEcCtD
Doxorubicin—Vision blurred—Epirubicin—urinary bladder cancer	3.95e-06	0.000116	CcSEcCtD
Doxorubicin—Cough—Methotrexate—urinary bladder cancer	3.91e-06	0.000115	CcSEcCtD
Doxorubicin—Ill-defined disorder—Epirubicin—urinary bladder cancer	3.89e-06	0.000114	CcSEcCtD
Doxorubicin—Convulsion—Methotrexate—urinary bladder cancer	3.88e-06	0.000114	CcSEcCtD
Doxorubicin—Vomiting—Etoposide—urinary bladder cancer	3.88e-06	0.000114	CcSEcCtD
Doxorubicin—Anaemia—Epirubicin—urinary bladder cancer	3.88e-06	0.000114	CcSEcCtD
Doxorubicin—Agitation—Epirubicin—urinary bladder cancer	3.86e-06	0.000113	CcSEcCtD
Doxorubicin—Rash—Etoposide—urinary bladder cancer	3.85e-06	0.000113	CcSEcCtD
Doxorubicin—Dermatitis—Etoposide—urinary bladder cancer	3.85e-06	0.000113	CcSEcCtD
Doxorubicin—Headache—Etoposide—urinary bladder cancer	3.83e-06	0.000112	CcSEcCtD
Doxorubicin—Chest pain—Methotrexate—urinary bladder cancer	3.82e-06	0.000112	CcSEcCtD
Doxorubicin—Arthralgia—Methotrexate—urinary bladder cancer	3.82e-06	0.000112	CcSEcCtD
Doxorubicin—Myalgia—Methotrexate—urinary bladder cancer	3.82e-06	0.000112	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	3.79e-06	0.000111	CcSEcCtD
Doxorubicin—Malaise—Epirubicin—urinary bladder cancer	3.78e-06	0.000111	CcSEcCtD
Doxorubicin—Discomfort—Methotrexate—urinary bladder cancer	3.77e-06	0.000111	CcSEcCtD
Doxorubicin—Vertigo—Epirubicin—urinary bladder cancer	3.77e-06	0.000111	CcSEcCtD
Doxorubicin—Syncope—Epirubicin—urinary bladder cancer	3.76e-06	0.00011	CcSEcCtD
Doxorubicin—Leukopenia—Epirubicin—urinary bladder cancer	3.76e-06	0.00011	CcSEcCtD
Doxorubicin—Palpitations—Epirubicin—urinary bladder cancer	3.71e-06	0.000109	CcSEcCtD
Doxorubicin—Confusional state—Methotrexate—urinary bladder cancer	3.69e-06	0.000108	CcSEcCtD
Doxorubicin—Loss of consciousness—Epirubicin—urinary bladder cancer	3.69e-06	0.000108	CcSEcCtD
Doxorubicin—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	3.68e-06	0.00549	CbGdCrCtD
Doxorubicin—Cough—Epirubicin—urinary bladder cancer	3.66e-06	0.000107	CcSEcCtD
Doxorubicin—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.66e-06	0.000107	CcSEcCtD
Doxorubicin—Convulsion—Epirubicin—urinary bladder cancer	3.64e-06	0.000107	CcSEcCtD
Doxorubicin—Infection—Methotrexate—urinary bladder cancer	3.64e-06	0.000107	CcSEcCtD
Doxorubicin—Nausea—Etoposide—urinary bladder cancer	3.63e-06	0.000107	CcSEcCtD
Doxorubicin—Hypertension—Epirubicin—urinary bladder cancer	3.62e-06	0.000106	CcSEcCtD
Doxorubicin—Nervous system disorder—Methotrexate—urinary bladder cancer	3.59e-06	0.000105	CcSEcCtD
Doxorubicin—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.58e-06	0.000105	CcSEcCtD
Doxorubicin—Chest pain—Epirubicin—urinary bladder cancer	3.57e-06	0.000105	CcSEcCtD
Doxorubicin—Arthralgia—Epirubicin—urinary bladder cancer	3.57e-06	0.000105	CcSEcCtD
Doxorubicin—Myalgia—Epirubicin—urinary bladder cancer	3.57e-06	0.000105	CcSEcCtD
Doxorubicin—Anxiety—Epirubicin—urinary bladder cancer	3.56e-06	0.000105	CcSEcCtD
Doxorubicin—Skin disorder—Methotrexate—urinary bladder cancer	3.55e-06	0.000104	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.55e-06	0.000104	CcSEcCtD
Doxorubicin—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.54e-06	0.000104	CcSEcCtD
Doxorubicin—Discomfort—Epirubicin—urinary bladder cancer	3.53e-06	0.000104	CcSEcCtD
Doxorubicin—Dry mouth—Epirubicin—urinary bladder cancer	3.49e-06	0.000103	CcSEcCtD
Doxorubicin—Anorexia—Methotrexate—urinary bladder cancer	3.49e-06	0.000102	CcSEcCtD
Doxorubicin—Confusional state—Epirubicin—urinary bladder cancer	3.45e-06	0.000101	CcSEcCtD
Doxorubicin—Oedema—Epirubicin—urinary bladder cancer	3.42e-06	0.000101	CcSEcCtD
Doxorubicin—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.42e-06	0.000101	CcSEcCtD
Doxorubicin—Hypotension—Methotrexate—urinary bladder cancer	3.42e-06	0.0001	CcSEcCtD
Doxorubicin—Infection—Epirubicin—urinary bladder cancer	3.4e-06	9.99e-05	CcSEcCtD
Doxorubicin—Shock—Epirubicin—urinary bladder cancer	3.37e-06	9.89e-05	CcSEcCtD
Doxorubicin—Nervous system disorder—Epirubicin—urinary bladder cancer	3.36e-06	9.86e-05	CcSEcCtD
Doxorubicin—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.35e-06	9.84e-05	CcSEcCtD
Doxorubicin—Tachycardia—Epirubicin—urinary bladder cancer	3.34e-06	9.81e-05	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.33e-06	9.79e-05	CcSEcCtD
Doxorubicin—Skin disorder—Epirubicin—urinary bladder cancer	3.33e-06	9.76e-05	CcSEcCtD
Doxorubicin—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.31e-06	9.72e-05	CcSEcCtD
Doxorubicin—Insomnia—Methotrexate—urinary bladder cancer	3.31e-06	9.72e-05	CcSEcCtD
Doxorubicin—Paraesthesia—Methotrexate—urinary bladder cancer	3.29e-06	9.65e-05	CcSEcCtD
Doxorubicin—Anorexia—Epirubicin—urinary bladder cancer	3.26e-06	9.58e-05	CcSEcCtD
Doxorubicin—Dyspnoea—Methotrexate—urinary bladder cancer	3.26e-06	9.58e-05	CcSEcCtD
Doxorubicin—Somnolence—Methotrexate—urinary bladder cancer	3.25e-06	9.55e-05	CcSEcCtD
Doxorubicin—Dyspepsia—Methotrexate—urinary bladder cancer	3.22e-06	9.46e-05	CcSEcCtD
Doxorubicin—Hypotension—Epirubicin—urinary bladder cancer	3.2e-06	9.39e-05	CcSEcCtD
Doxorubicin—Decreased appetite—Methotrexate—urinary bladder cancer	3.18e-06	9.34e-05	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.16e-06	9.27e-05	CcSEcCtD
Doxorubicin—Fatigue—Methotrexate—urinary bladder cancer	3.15e-06	9.26e-05	CcSEcCtD
Doxorubicin—Pain—Methotrexate—urinary bladder cancer	3.13e-06	9.19e-05	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.12e-06	9.16e-05	CcSEcCtD
Doxorubicin—Insomnia—Epirubicin—urinary bladder cancer	3.1e-06	9.09e-05	CcSEcCtD
Doxorubicin—Paraesthesia—Epirubicin—urinary bladder cancer	3.07e-06	9.03e-05	CcSEcCtD
Doxorubicin—Dyspnoea—Epirubicin—urinary bladder cancer	3.05e-06	8.96e-05	CcSEcCtD
Doxorubicin—Somnolence—Epirubicin—urinary bladder cancer	3.04e-06	8.94e-05	CcSEcCtD
Doxorubicin—Feeling abnormal—Methotrexate—urinary bladder cancer	3.02e-06	8.85e-05	CcSEcCtD
Doxorubicin—Dyspepsia—Epirubicin—urinary bladder cancer	3.01e-06	8.85e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.99e-06	8.78e-05	CcSEcCtD
Doxorubicin—Decreased appetite—Epirubicin—urinary bladder cancer	2.98e-06	8.74e-05	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.96e-06	8.68e-05	CcSEcCtD
Doxorubicin—Fatigue—Epirubicin—urinary bladder cancer	2.95e-06	8.67e-05	CcSEcCtD
Doxorubicin—Constipation—Epirubicin—urinary bladder cancer	2.93e-06	8.6e-05	CcSEcCtD
Doxorubicin—Pain—Epirubicin—urinary bladder cancer	2.93e-06	8.6e-05	CcSEcCtD
Doxorubicin—Urticaria—Methotrexate—urinary bladder cancer	2.91e-06	8.53e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Methotrexate—urinary bladder cancer	2.89e-06	8.49e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Methotrexate—urinary bladder cancer	2.89e-06	8.49e-05	CcSEcCtD
Doxorubicin—Feeling abnormal—Epirubicin—urinary bladder cancer	2.82e-06	8.28e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.8e-06	8.22e-05	CcSEcCtD
Doxorubicin—Urticaria—Epirubicin—urinary bladder cancer	2.72e-06	7.99e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Epirubicin—urinary bladder cancer	2.71e-06	7.95e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Epirubicin—urinary bladder cancer	2.71e-06	7.95e-05	CcSEcCtD
Doxorubicin—Hypersensitivity—Methotrexate—urinary bladder cancer	2.7e-06	7.91e-05	CcSEcCtD
Doxorubicin—Asthenia—Methotrexate—urinary bladder cancer	2.63e-06	7.71e-05	CcSEcCtD
Doxorubicin—Pruritus—Methotrexate—urinary bladder cancer	2.59e-06	7.6e-05	CcSEcCtD
Doxorubicin—Hypersensitivity—Epirubicin—urinary bladder cancer	2.52e-06	7.41e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Methotrexate—urinary bladder cancer	2.5e-06	7.35e-05	CcSEcCtD
Doxorubicin—Asthenia—Epirubicin—urinary bladder cancer	2.46e-06	7.21e-05	CcSEcCtD
Doxorubicin—Pruritus—Epirubicin—urinary bladder cancer	2.42e-06	7.11e-05	CcSEcCtD
Doxorubicin—Dizziness—Methotrexate—urinary bladder cancer	2.42e-06	7.1e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Epirubicin—urinary bladder cancer	2.34e-06	6.88e-05	CcSEcCtD
Doxorubicin—Vomiting—Methotrexate—urinary bladder cancer	2.33e-06	6.83e-05	CcSEcCtD
Doxorubicin—Rash—Methotrexate—urinary bladder cancer	2.31e-06	6.77e-05	CcSEcCtD
Doxorubicin—Dermatitis—Methotrexate—urinary bladder cancer	2.3e-06	6.77e-05	CcSEcCtD
Doxorubicin—Headache—Methotrexate—urinary bladder cancer	2.29e-06	6.73e-05	CcSEcCtD
Doxorubicin—Dizziness—Epirubicin—urinary bladder cancer	2.26e-06	6.65e-05	CcSEcCtD
Doxorubicin—Vomiting—Epirubicin—urinary bladder cancer	2.18e-06	6.39e-05	CcSEcCtD
Doxorubicin—Nausea—Methotrexate—urinary bladder cancer	2.17e-06	6.38e-05	CcSEcCtD
Doxorubicin—Rash—Epirubicin—urinary bladder cancer	2.16e-06	6.34e-05	CcSEcCtD
Doxorubicin—Dermatitis—Epirubicin—urinary bladder cancer	2.16e-06	6.33e-05	CcSEcCtD
Doxorubicin—Headache—Epirubicin—urinary bladder cancer	2.15e-06	6.3e-05	CcSEcCtD
Doxorubicin—Nausea—Epirubicin—urinary bladder cancer	2.03e-06	5.97e-05	CcSEcCtD
Doxorubicin—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.2e-06	6.54e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ERCC2—urinary bladder cancer	1.2e-06	6.52e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CDKN1A—urinary bladder cancer	1.19e-06	6.48e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—CREBBP—urinary bladder cancer	1.19e-06	6.48e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PTEN—urinary bladder cancer	1.18e-06	6.47e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.17e-06	6.38e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GPX1—urinary bladder cancer	1.17e-06	6.37e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—RHOA—urinary bladder cancer	1.17e-06	6.36e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TERT—urinary bladder cancer	1.15e-06	6.3e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ERCC2—urinary bladder cancer	1.15e-06	6.25e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.15e-06	6.25e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—MYC—urinary bladder cancer	1.14e-06	6.24e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NCOR1—urinary bladder cancer	1.14e-06	6.22e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EP300—urinary bladder cancer	1.13e-06	6.17e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—MTHFR—urinary bladder cancer	1.12e-06	6.13e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PPARG—urinary bladder cancer	1.12e-06	6.13e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—EGFR—urinary bladder cancer	1.12e-06	6.11e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.11e-06	6.08e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—SRC—urinary bladder cancer	1.1e-06	6e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NQO1—urinary bladder cancer	1.1e-06	5.98e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CDKN1A—urinary bladder cancer	1.09e-06	5.96e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.09e-06	5.96e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PTEN—urinary bladder cancer	1.09e-06	5.94e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTGS2—urinary bladder cancer	1.08e-06	5.92e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CREBBP—urinary bladder cancer	1.08e-06	5.89e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—ERBB2—urinary bladder cancer	1.08e-06	5.89e-05	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—urinary bladder cancer	1.08e-06	5.88e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—MTHFR—urinary bladder cancer	1.08e-06	5.88e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—RRM2—urinary bladder cancer	1.08e-06	5.88e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ERCC2—urinary bladder cancer	1.07e-06	5.85e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CREBBP—urinary bladder cancer	1.07e-06	5.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—FGFR3—urinary bladder cancer	1.06e-06	5.79e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—KRAS—urinary bladder cancer	1.06e-06	5.77e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTGS2—urinary bladder cancer	1.05e-06	5.76e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IGF1—urinary bladder cancer	1.05e-06	5.76e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.05e-06	5.75e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTGS2—urinary bladder cancer	1.05e-06	5.71e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GSTP1—urinary bladder cancer	1.04e-06	5.67e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EP300—urinary bladder cancer	1.04e-06	5.67e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.03e-06	5.65e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.03e-06	5.65e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ESR1—urinary bladder cancer	1.03e-06	5.62e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—HRAS—urinary bladder cancer	1.03e-06	5.6e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.02e-06	5.57e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.02e-06	5.55e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—SRC—urinary bladder cancer	1.01e-06	5.51e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MTHFR—urinary bladder cancer	1.01e-06	5.5e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.01e-06	5.49e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GSTP1—urinary bladder cancer	1.01e-06	5.49e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TERT—urinary bladder cancer	1e-06	5.49e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	9.98e-07	5.45e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	9.97e-07	5.44e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ENO2—urinary bladder cancer	9.97e-07	5.44e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—MYC—urinary bladder cancer	9.85e-07	5.38e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	9.76e-07	5.33e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.72e-07	5.31e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTGS2—urinary bladder cancer	9.72e-07	5.31e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	9.67e-07	5.28e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—TYMS—urinary bladder cancer	9.66e-07	5.27e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—RHOA—urinary bladder cancer	9.66e-07	5.27e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EGFR—urinary bladder cancer	9.63e-07	5.26e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TYMP—urinary bladder cancer	9.59e-07	5.23e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—NCOR1—urinary bladder cancer	9.55e-07	5.21e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GSTM1—urinary bladder cancer	9.55e-07	5.21e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	9.46e-07	5.16e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTEN—urinary bladder cancer	9.45e-07	5.16e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—urinary bladder cancer	9.39e-07	5.13e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—TYMS—urinary bladder cancer	9.34e-07	5.1e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	9.3e-07	5.08e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GSTM1—urinary bladder cancer	9.24e-07	5.04e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—NCOR1—urinary bladder cancer	9.24e-07	5.04e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	9.22e-07	5.03e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—FGFR3—urinary bladder cancer	9.22e-07	5.03e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CDKN1A—urinary bladder cancer	9.22e-07	5.03e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTEN—urinary bladder cancer	9.2e-07	5.02e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NAT2—urinary bladder cancer	9.2e-07	5.02e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GPX1—urinary bladder cancer	9.15e-07	4.99e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GSTP1—urinary bladder cancer	9.14e-07	4.99e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTEN—urinary bladder cancer	9.12e-07	4.98e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PPARG—urinary bladder cancer	9.11e-07	4.97e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—KRAS—urinary bladder cancer	9.1e-07	4.97e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—MYC—urinary bladder cancer	9.05e-07	4.94e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CREBBP—urinary bladder cancer	9.02e-07	4.92e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—EP300—urinary bladder cancer	9.01e-07	4.92e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—HRAS—urinary bladder cancer	8.98e-07	4.9e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ERCC2—urinary bladder cancer	8.98e-07	4.9e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ERBB2—urinary bladder cancer	8.94e-07	4.88e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IGF1—urinary bladder cancer	8.91e-07	4.86e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EGFR—urinary bladder cancer	8.85e-07	4.83e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GPX1—urinary bladder cancer	8.85e-07	4.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTGS2—urinary bladder cancer	8.84e-07	4.82e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EP300—urinary bladder cancer	8.77e-07	4.79e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CREBBP—urinary bladder cancer	8.75e-07	4.78e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PPARG—urinary bladder cancer	8.73e-07	4.77e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—EP300—urinary bladder cancer	8.7e-07	4.75e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ERCC2—urinary bladder cancer	8.68e-07	4.74e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NAT2—urinary bladder cancer	8.67e-07	4.73e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—SRC—urinary bladder cancer	8.53e-07	4.66e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	8.52e-07	4.65e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—TYMS—urinary bladder cancer	8.5e-07	4.64e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL8—urinary bladder cancer	8.48e-07	4.63e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTEN—urinary bladder cancer	8.48e-07	4.63e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—MTHFR—urinary bladder cancer	8.44e-07	4.61e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NCOR1—urinary bladder cancer	8.4e-07	4.59e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GSTM1—urinary bladder cancer	8.4e-07	4.59e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CREBBP—urinary bladder cancer	8.39e-07	4.58e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—KRAS—urinary bladder cancer	8.36e-07	4.56e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	8.2e-07	4.47e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—MTHFR—urinary bladder cancer	8.16e-07	4.46e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—RHOA—urinary bladder cancer	8.16e-07	4.46e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL2—urinary bladder cancer	8.1e-07	4.42e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—EP300—urinary bladder cancer	8.09e-07	4.41e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GPX1—urinary bladder cancer	8.05e-07	4.39e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	8.04e-07	4.39e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NQO1—urinary bladder cancer	8.04e-07	4.39e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—RRM2—urinary bladder cancer	7.94e-07	4.33e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ERCC2—urinary bladder cancer	7.9e-07	4.31e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCND1—urinary bladder cancer	7.9e-07	4.31e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CREBBP—urinary bladder cancer	7.85e-07	4.29e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	7.84e-07	4.28e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—HRAS—urinary bladder cancer	7.73e-07	4.22e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTEN—urinary bladder cancer	7.71e-07	4.21e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MMP9—urinary bladder cancer	7.67e-07	4.19e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MYC—urinary bladder cancer	7.65e-07	4.17e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CDKN1A—urinary bladder cancer	7.64e-07	4.17e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PTEN—urinary bladder cancer	7.63e-07	4.16e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ERBB2—urinary bladder cancer	7.56e-07	4.12e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—RRM2—urinary bladder cancer	7.48e-07	4.08e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EGFR—urinary bladder cancer	7.48e-07	4.08e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—MTHFR—urinary bladder cancer	7.43e-07	4.05e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	7.35e-07	4.01e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ENO2—urinary bladder cancer	7.35e-07	4.01e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—EP300—urinary bladder cancer	7.35e-07	4.01e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EP300—urinary bladder cancer	7.27e-07	3.97e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—urinary bladder cancer	7.17e-07	3.91e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL8—urinary bladder cancer	7.16e-07	3.91e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	7.13e-07	3.89e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—HRAS—urinary bladder cancer	7.11e-07	3.88e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—RHOA—urinary bladder cancer	7.1e-07	3.88e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—SRC—urinary bladder cancer	7.07e-07	3.86e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—KRAS—urinary bladder cancer	7.06e-07	3.86e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	6.93e-07	3.78e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ENO2—urinary bladder cancer	6.93e-07	3.78e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—urinary bladder cancer	6.87e-07	3.75e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL2—urinary bladder cancer	6.85e-07	3.74e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PPARG—urinary bladder cancer	6.84e-07	3.74e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	6.72e-07	3.67e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	6.7e-07	3.66e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.68e-07	3.65e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCND1—urinary bladder cancer	6.68e-07	3.64e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PPARG—urinary bladder cancer	6.62e-07	3.61e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CREBBP—urinary bladder cancer	6.57e-07	3.59e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ERBB2—urinary bladder cancer	6.57e-07	3.59e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MMP9—urinary bladder cancer	6.48e-07	3.54e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CDKN1A—urinary bladder cancer	6.46e-07	3.52e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PTEN—urinary bladder cancer	6.44e-07	3.52e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—urinary bladder cancer	6.43e-07	3.51e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CREBBP—urinary bladder cancer	6.36e-07	3.47e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MYC—urinary bladder cancer	6.34e-07	3.46e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.27e-07	3.42e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTEN—urinary bladder cancer	6.25e-07	3.41e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—TYMS—urinary bladder cancer	6.23e-07	3.4e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EGFR—urinary bladder cancer	6.2e-07	3.38e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	6.16e-07	3.36e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	6.16e-07	3.36e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EP300—urinary bladder cancer	6.14e-07	3.35e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PPARG—urinary bladder cancer	6.02e-07	3.29e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HRAS—urinary bladder cancer	6.01e-07	3.28e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTEN—urinary bladder cancer	5.99e-07	3.27e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SRC—urinary bladder cancer	5.97e-07	3.26e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—EP300—urinary bladder cancer	5.96e-07	3.25e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NQO1—urinary bladder cancer	5.93e-07	3.24e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GPX1—urinary bladder cancer	5.9e-07	3.22e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KRAS—urinary bladder cancer	5.86e-07	3.2e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	5.79e-07	3.16e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CREBBP—urinary bladder cancer	5.79e-07	3.16e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—EP300—urinary bladder cancer	5.71e-07	3.12e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.67e-07	3.09e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CDKN1A—urinary bladder cancer	5.62e-07	3.07e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTEN—urinary bladder cancer	5.61e-07	3.06e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NQO1—urinary bladder cancer	5.59e-07	3.05e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	5.44e-07	2.97e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—urinary bladder cancer	5.38e-07	2.94e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MYC—urinary bladder cancer	5.35e-07	2.92e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EP300—urinary bladder cancer	5.35e-07	2.92e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EGFR—urinary bladder cancer	5.24e-07	2.86e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—urinary bladder cancer	5.21e-07	2.84e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—urinary bladder cancer	5.2e-07	2.84e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SRC—urinary bladder cancer	5.2e-07	2.84e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—HRAS—urinary bladder cancer	4.98e-07	2.72e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KRAS—urinary bladder cancer	4.95e-07	2.7e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	4.94e-07	2.7e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.89e-07	2.67e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—urinary bladder cancer	4.74e-07	2.59e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTEN—urinary bladder cancer	4.7e-07	2.56e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MYC—urinary bladder cancer	4.66e-07	2.54e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	4.66e-07	2.54e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TYMS—urinary bladder cancer	4.6e-07	2.51e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGFR—urinary bladder cancer	4.56e-07	2.49e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	4.54e-07	2.48e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	4.54e-07	2.48e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTEN—urinary bladder cancer	4.54e-07	2.48e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.53e-07	2.47e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.53e-07	2.47e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—EP300—urinary bladder cancer	4.48e-07	2.44e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PPARG—urinary bladder cancer	4.41e-07	2.41e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—urinary bladder cancer	4.4e-07	2.4e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.39e-07	2.4e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.35e-07	2.37e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TYMS—urinary bladder cancer	4.33e-07	2.36e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—EP300—urinary bladder cancer	4.33e-07	2.36e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KRAS—urinary bladder cancer	4.3e-07	2.35e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.28e-07	2.34e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.28e-07	2.34e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.27e-07	2.33e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	4.24e-07	2.31e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HRAS—urinary bladder cancer	4.21e-07	2.3e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTEN—urinary bladder cancer	4.13e-07	2.26e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GPX1—urinary bladder cancer	4.1e-07	2.24e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	4.03e-07	2.2e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.02e-07	2.19e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—EP300—urinary bladder cancer	3.94e-07	2.15e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.78e-07	2.07e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HRAS—urinary bladder cancer	3.66e-07	2e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.65e-07	1.99e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	3.47e-07	1.9e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.26e-07	1.78e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.13e-07	1.71e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.07e-07	1.67e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.05e-07	1.66e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTEN—urinary bladder cancer	3.03e-07	1.65e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.95e-07	1.61e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—EP300—urinary bladder cancer	2.89e-07	1.58e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.83e-07	1.55e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.8e-07	1.53e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.8e-07	1.53e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.68e-07	1.46e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.63e-07	1.44e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.56e-07	1.4e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.47e-07	1.35e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.41e-07	1.32e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.23e-07	1.22e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—EP300—urinary bladder cancer	2.13e-07	1.16e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.1e-07	1.15e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.01e-07	1.1e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.01e-07	1.09e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.93e-07	1.05e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.58e-07	8.61e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.38e-07	7.51e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.31e-07	7.16e-06	CbGpPWpGaD
